| Literature DB >> 32130256 |
Achini Adikari1, Daswin de Silva1, Weranja K B Ranasinghe1,2, Tharindu Bandaragoda1, Oshadi Alahakoon3, Raj Persad4, Nathan Lawrentschuk5,6,7, Damminda Alahakoon1, Damien Bolton5.
Abstract
BACKGROUND: Online Cancer Support Groups (OCSG) are becoming an increasingly vital source of information, experiences and empowerment for patients with cancer. Despite significant contributions to physical, psychological and emotional wellbeing of patients, OCSG are yet to be formally recognised and used in multidisciplinary cancer support programs. This study highlights the opportunity of using Artificial Intelligence (AI) in OCSG to address psychological morbidity, with supporting empirical evidence from prostate cancer (PCa) patients.Entities:
Mesh:
Year: 2020 PMID: 32130256 PMCID: PMC7055800 DOI: 10.1371/journal.pone.0229361
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The patient distribution across the ten selected OCSG.
| Online support groups | URL | n (% in total) |
|---|---|---|
| Healingwell | 2 520 (39.0) | |
| Cancer orums | 873 (13.5) | |
| Cancer Survivors Network | csn.cancer.org/forum | 810 (12.5) |
| Healthboards | 429 (6.6) | |
| Prostate cancer info link | prostatecancerinfolink.ning.com/forum | 396 (6.1) |
| Cancer compass | 356 (5.5) | |
| Prostate cancer UK | community.prostatecanceruk.org | 308 (4.8) |
| Patient info | patient.info/forums | 299 (4.6) |
| Us too | 236 (3.7) | |
| Macmillan UK | community.macmillan.org.uk | 230 (3.6) |
Fig 1The extraction of patient-reported reasons for joining and emotions from a sample of anonymised OCSG discussions.
Patient characteristics (percentages calculated based on ‘Gleason score known’ population and ‘Age known’ population respectively).
| n (%) | |
|---|---|
| < = 6 | 3895 (49.92) |
| 7 | 2401 (30.77) |
| >7 | 1507 (19.31) |
| <40 | 532 (5.18) |
| 41–50 | 1331 (12.97) |
| 51–60 | 2630 (25.63) |
| 61–70 | 4237 (41.28) |
| >70 | 1533 (14.94) |
| Surgery | 7394 (62.58) |
| Radiation | 3810 (32.24) |
| Active Surveillance | 612 (5.18) |
Main discussion topics and sub-topics discussed in the identified groups.
| Topic category | Volume (%) |
|---|---|
| • Surgery options | 18.93% |
| • Radiation | 11.42% |
| • Active surveillance | 5.86% |
| • Hormone therapy | 8.80% |
| • Making decisions | 5.45% |
| • Discussing test results | 10.22% |
| • Asking for clinician recommendations | 6.44% |
| • Seeking advice/experiences | 6.60% |
| • Treatment options | 0.85% |
| • Urinary Incontinence | 8.41% |
| • Erectile dysfunction | 5.49% |
| • Other (Hernia, Tiredness, Stroke, Clot) | 2.84% |
| • Bleeding and Infection | 3.19% |
| • Biopsy results | 1.10% |
| • Metastasis cancer | 0.93% |
| • Treatment/ therapy options | 0.97% |
| • Active surveillance | 0.35% |
| • Discussing PCa prevention | 3.23% |
| • Experience sharing related to coping | 0.88% |
| • Information on hospitals/new drugs/ Insurance | 2.64% |
| • Diet/ Lifestyle | 2.73% |
Fig 2Continuum of emotions expressed in the first post by all participants (a) and the comparison of emotions based on the first post based on each identified group (b).
Characteristics of patient groups: Pre and post-treatment.
| Pre-treatment n (% in Pre-treatment) | Post-treatment n (% in Post-treatment) | n (% in Total) | 95% CI | ||
|---|---|---|---|---|---|
| 242 | 489 | 731 | |||
| <7 | 148 (61.16) | 288 (57.49) | 436 (58.68) | 0.3414 | -3.9073 to 11.0285 |
| 7 | 65 (26.86) | 165 (32.93) | 230 (30.96) | 0.0937 | -1.0538 to 12.7669 |
| >7 | 29 (11.98) | 48 (9.58) | 77 (10.36) | 0.3148 | -2.1475 to 7.6199 |
| <40 | 7 (2.89) | 10 (2) | 17 (2.29) | 0.4059 | -1.2521 to 4.0991 |
| 41–50 | 36 (14.88) | 70 (13.97) | 106 (14.27) | 0.7398 | -4.2314 to 6.6497 |
| 51–60 | 98 (40.5) | 189 (37.72) | 287 (38.63) | 0.4661 | -4.6064 to 10.3048 |
| 61–70 | 79 (32.64) | 163 (32.53) | 242 (32.57) | 0.9761 | -6.9002 to 7.4131 |
| >70 | 22 (9.09) | 69 (13.77) | 91 (12.25) | 0.0684 | -0.4111 to 9.1426 |
| Sexual symptoms reported | 116 (47.93) | 276 (55.09) | 392 (52.76) | 0.0671 | -0.4930 to 14.7157 |
| Urinary symptoms reported | 191 (78.93) | 420 (83.83) | 611 (82.23) | 0.1017 | -0.9201 to 11.2096 |
Fig 3Negative emotions over a time period of 12 months analysed separately for the four groups; diagnosis, treatment, side-effects, recurrence and negative emotion fluctuations for pre-treatment and post-treatment groups separately (confidence intervals are based on standard error).